Recursion Pharmaceuticals (RXRX) said Wednesday that it has completed its business combination with Exscientia (EXAI) and Exscientia is now a wholly owned unit of Recursion.
Exscientia's American depositary shares have stopped trading and will be delisted from Nasdaq, according to Recursion.
The combined company has received about $450 million in upfront and milestone payments from partners and has more than 10 partnered programs in areas such as oncology and immunology, Recursion added.
The deal was first announced in August.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments